Clinical Rheumatology

, Volume 12, Issue 4, pp 500–505 | Cite as

The effect of methylprednisolone pulse therapy on methotrexate treatment of rheumatoid arthritis

  • M. J. Van Der Veen
  • J. W. J. Bijlsma
Originals

Summary

We randomly assigned 30 active rheumatoid arthritis (RA) patients who started oral methotrexate (MTX, 7.5 mg/week) treatment, into 3 groups. Group I received no additional corticosteroids; Group II was treated with 3 oral pulses of 100 mg prednisolone and Group III with 3 intravenous pulses of 1000 mg methylprednisolone (MP) on alternate days during the first week. Parameters of disease activity were measured at the start, after 10 days and at regular intervals up to 1 year. In Group I maximal improvement occurred after 18 weeks and in Group III after 6 weeks. This effect was sustained during the study. The initial effects in Group II were not as strong as in Group III and of shorter duration. No serious side effects were noticed. Our results suggest, that MP-pulse therapy seems to be useful in bridging the gap between the introduction of MTX and the response to this drug. Furthermore, we found that patients who were HLA-DR4-positive showed a better clinical response after 1 year than HLA-DR4-negative patients.

Key words

Corticosteroid Treatment Intravenous Methylprednisolone Pulses Oral Prednisolone Pulses Methotrexate Rheumatoid Arthritis Disease Activity 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Weinblatt, M.E., Kaplan, H., Germain, B.F., Merriman, R.C., Solomon, S.D., Wall, B., Anderson, L., Block, S., Small, R., Wolfe, F., Gall, E., Torretti, D., Polisson, R. Methotrexate in rheumatoid arthritis: effects on disease activity in a multicenter prospective study. J Rheum 1991, 18, 334–338.PubMedGoogle Scholar
  2. 2.
    Andersen, P.A., West, S.G., O'Dell, J.R., Via, Ch.S., Claypool, R.G., Kotzin, B.L. Weekly pulse methotrexate in rheumatoid arthritis. Ann Int Med 1985, 103, 489–496.PubMedGoogle Scholar
  3. 3.
    Olsen, N.J., Murray, L.M. Antiproliferative effects of methotrexate on peripheral blood mononuclear cells. Arthritis Rheum 1989, 32, 378–385.PubMedGoogle Scholar
  4. 4.
    Williams, H.J., Willkens, R.F., Samuelson, C.O. Jr., Alarcón, G.S., Guttadauria, M., Yarboro, Ch., Polisson, R.P., Weiner, S.R., Luggen, M.E., Billingsley, L.M., Dahl, S.L., Egger, M.J., Reading, J.C., Ward, J.R. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1985, 28, 721–730.PubMedGoogle Scholar
  5. 5.
    Sambrook, P.N., Champion, G.D., Browne, C.D., Cohen, M.L., Compton, P., Day, R.O., Jager, de, J. Comparison of methotrexate with azathioprine or 6-mercaptopurine in refractory rheumatoid arthritis: a life-table analysis. Br J Rheum 1986, 25, 372–375.Google Scholar
  6. 6.
    Neumann, V., Hopkins, R., Dixon, J., Watkins, A., Bird, H., Wright, V. Combination therapy with pulsed methylprednisolone in rheumatoid arthritis. Ann Rheum Dis 1985, 44, 747–751.PubMedGoogle Scholar
  7. 7.
    Bijlsma, J.W.J., Schenk, Y., Ramselaar, A.C.P., Huber-Bruning, O. Methylprednisolone pulse therapy in conjunction with azathioprine in rheumatoid arthritis. Clin Rheum 1986, 5, 499–504.Google Scholar
  8. 8.
    Williams, I.A., Bayliss, E.M., Shipley, M.E. A double-blind placebo-controlled trial of methylprednisolone pulse therapy in active rheumatoid disease. Lancet 1982, ii, 237–240.Google Scholar
  9. 9.
    Forster, P.J.G., Grindulis, K.A., Neumann, V., Hubball, S., McConkey, B. High-dose intravenous methylprednisolone in rheumatoid arthritis. Ann Rheum Dis 1982, 41, 444–446.PubMedGoogle Scholar
  10. 10.
    Ropes, M.W., Bennett, G.A., Caleb, S., Jacox, R., Jessar, R.A. Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 1958, 9, 175–176.PubMedGoogle Scholar
  11. 11.
    Ritchie, D.M., Boyle, J.A., McInnes, J.M., Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Quart J Med 1968, 37, 393–406.PubMedGoogle Scholar
  12. 12.
    Stastny, P. Association of the B-cell allo-antigen DRw4 with rheumatoid arthritis. N Engl J Med 1978, 298, 869–871.PubMedGoogle Scholar
  13. 13.
    Westedt, M.L., Breedveld, F.C., Schreuder, G.M.Th., D'Amaro, J., Cats, A., de Vries, R.R.P. Immunogenetic heterogeneity of rheumatoid arthritis. Ann Rheum Dis 1986, 45, 534–538.PubMedGoogle Scholar
  14. 14.
    Weinstein, A. Long-term efficacy of methotrexate in rheumatoid arthritis. In: Methotrexate therapy in rheumatic disease. Ed.: Wilke, W.S., New York, Marcel Dekker, Inc., 1989, 91–101.Google Scholar

Copyright information

© Clinical Rheumatology 1993

Authors and Affiliations

  • M. J. Van Der Veen
    • 1
  • J. W. J. Bijlsma
    • 1
  1. 1.Dept. of Rheumatology F 02.223University Hospital UtrechtUtrechtThe Netherlands

Personalised recommendations